Pseudotyped GFP VSV (VSV-PS02)

Product Overview
Pseudotyped GFP VSV is designed as a control for CD's Pseudotyped GFP rSARS-CoV-2 Spike to test for non-specific factors that affect virus infectivity. The Pseudovirus display the VSV envelope glycoprotein (VSV-G) pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. Pseudovirus is capable of a single round of infection and carry a genome that expresses GFP optical reporter gene upon infection. VSV Pseudovirus is produced in HEK-293T cells using three separate plasmids, encoding VSV-G, a lentiviral gag polyprotein, and a reporter gene. VSV Pseudovirus is created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so).
Nature
Virus
Application Notes
Ideal as a negative control pseudovirus particles for the Pseudotyped GFP rSARS-CoV-2 Spike, CD Cat# COV-PS02 or other pseudovirus particles used to to test for non-specific factors that affect virus infectivity
Size
1 mL
Buffer
20% FBS/DMEM
Storage
Store at -80°C. Multiple freeze/thaw cycles not recommended.
When using the virus, transfer the virus from the -80 ° C refrigerator and melt it in an ice bath.
Ship
Frozen on dry ice
Warnings
Biosafety Level:    BSL-2
It is the responsibility of the principal investigator to seek Institutional Biosafety Safety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.

Citations


Have you cited VSV-PS02 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review

CYTOMETRY PART A

Authors: Benlyamani, Ihsane; Venet, Fabienne; Coudereau, Remy; Gossez, Morgane; Monneret, Guillaume

Several months after the sudden emergence of SARS-CoV-2 and COVID-19, the understanding of the appropriate host immune response to a virus totally unknown of human immune surveillance is still of major importance. By international definition, COVID-19 falls in the scope of septic syndromes (organ dysfunction due to dysregulated host response to an infection) in which immunosuppression is a significant driver of mortality. Sepsis-induced immunosuppression is mostly defined and monitored by the measurement of decreased expression of HLA-DR molecules on circulating monocytes (mHLA-DR). In this interim review, we summarize the first mHLA-DR results in COVID-19 patients. In critically ill patients, results homogenously indicate a decreased mHLA-DR expression, which, along with profound lymphopenia and other functional alterations, is indicative of a status of immunosuppression. (c) 2020 International Society for Advancement of Cytometry

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

Authors: D'Amico, Ferdinando; Danese, Silvio; Peyrin-Biroulet, Laurent

BACKGROUND & AIMS: Data on the clinical characteristics of patients with inflammatory bowel diseases (IBDs) with coronavirus disease 2019 (COVID-19) are scarce. The aim of our systematic review was to investigate symptoms and diagnostic-therapeutic management of IBD patients with COVID-19. METHODS: We searched PubMed, Embase, Web of Science, and MedRxiv up to July 29, 2020, to identify all studies reporting clinical information on adult and pediatric IBD patients with confirmed COVID-19. RESULTS: Twenty-three studies met our inclusion criteria, including 243,760 IBD patients. COVID-19 was diagnosed in 1028 patients (509 with Crohn's disease [49.5%], 428 with ulcerative colitis [41.6%], 49 with indeterminate colitis [4.8%], and 42 with missing data [4.1%]), accounting for a cumulative prevalence of 0.4%. Viral infection occurred more frequently in males than in females (56.5% vs 39.7%), and the mean age ranged from 14 to 85 years. The most common symptoms were fever (48.3%), cough (46.5%), and diarrhea (20.5%), and a COVID-19 diagnosis was achieved mainly through polymerase chain reaction analysis of nasopharyngeal swabs (94.4%) and chest computed tomography scans (38.9%). Hydroxychloroquine (23.9%), lopinavir/ritonavir (8.2%), steroids (3.2%), and antibiotics (3.1%) were the most used drugs. Overall, approximately a third of patients were hospitalized (30.6%), and 11.4% of them required admission to the intensive care unit. In total, 29 COVID-19-related deaths were reported (3.8%), and increasing age and the presence of comorbidities were recognized as risk factors for COVID-19 and negative outcomes. CONCLUSIONS: Diarrhea occurs more frequently in IBD patients with COVID-19 than in the non-IBD population. Further studies are needed to define the optimal diagnostic-therapeutic approach in IBD patients with COVID-19.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket